{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:45:36Z","timestamp":1792813536726,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40264-018-0674-y","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T03:00:06Z","timestamp":1525748406000},"page":"835-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety of Tamsulosin: A Systematic Review of Randomized Trials with a Focus on Women and Children"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-7306","authenticated-orcid":false,"given":"Steven A.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal I.","family":"Chughtai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"674_CR1","unstructured":"American Urological Association Guideline. Management of benign prostatic hyperplasia (BPH). American Urological Association Education and Research, Inc. 2010. \n                    https:\/\/www.auanet.org\/guidelines\/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014\n                    \n                  ). Accessed 21 June 2017."},{"key":"674_CR2","unstructured":"Flomax prescribing information. \n                    http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Flomax%20Caps\/Flomax.pdf\n                    \n                  . Accessed 21 June 2017."},{"key":"674_CR3","doi-asserted-by":"publisher","unstructured":"Campschroer T, Zhu Y, Duijvesz D, Grobbee DE, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev. 2014;(4):CD008509. \n                    https:\/\/doi.org\/10.1002\/14651858.cd008509.pub2\n                    \n                  .","DOI":"10.1002\/14651858.cd008509.pub2"},{"key":"674_CR4","doi-asserted-by":"publisher","first-page":"16031","DOI":"10.1038\/nrdp.2016.31","volume":"2","author":"B Chughtai","year":"2016","unstructured":"Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016;2:16031. \n                    https:\/\/doi.org\/10.1038\/nrdp.2016.31\n                    \n                  .","journal-title":"Nat Rev Dis Primers."},{"issue":"6","key":"674_CR5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1517\/17425255.4.6.771","volume":"4","author":"CC Schulman","year":"2008","unstructured":"Schulman CC. Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Expert Opin Drug Metab Toxicol. 2008;4(6):771\u201382. \n                    https:\/\/doi.org\/10.1517\/17425255.4.6.771\n                    \n                  .","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"3","key":"674_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1185\/03007995.2013.766594","volume":"29","author":"J Yuan","year":"2013","unstructured":"Yuan J, Liu Y, Yang Z, Qin X, Yang K, Mao C. The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. Curr Med Res Opin. 2013;29(3):279\u201387. \n                    https:\/\/doi.org\/10.1185\/03007995.2013.766594\n                    \n                  .","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"674_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2310\/8000.2013.131012","volume":"16","author":"C Malo","year":"2014","unstructured":"Malo C, Audette-C\u00f4t\u00e9 JS, Emond M, Turgeon AF. Tamsulosin for treatment of unilateral distal ureterolithiasis: a systematic review and meta-analysis. CJEM. 2014;16(3):229\u201342.","journal-title":"CJEM."},{"issue":"6","key":"674_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jpurol.2015.04.036","volume":"11","author":"N Vel\u00e1zquez","year":"2015","unstructured":"Vel\u00e1zquez N, Zapata D, Wang HH, Wiener JS, Lipkin ME, Routh JC. Medical expulsive therapy for pediatric urolithiasis: systematic review and meta-analysis. J Pediatr Urol. 2015;11(6):321\u20137. \n                    https:\/\/doi.org\/10.1016\/j.jpurol.2015.04.036\n                    \n                  .","journal-title":"J Pediatr Urol."},{"key":"674_CR9","doi-asserted-by":"publisher","unstructured":"Fisher E, Subramonian K, Omar MI. The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men. Cochrane Database Syst Rev. 2014;(6):CD006744. \n                    https:\/\/doi.org\/10.1002\/14651858.cd006744.pub3\n                    \n                  .","DOI":"10.1002\/14651858.cd006744.pub3"},{"issue":"Suppl 3","key":"674_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1464-410X.2008.07496.x","volume":"101","author":"JC Nickel","year":"2008","unstructured":"Nickel JC. Role of alpha1-blockers in chronic prostatitis syndromes. BJU Int. 2008;101(Suppl 3):11\u20136. \n                    https:\/\/doi.org\/10.1111\/j.1464-410X.2008.07496.x\n                    \n                  .","journal-title":"BJU Int."},{"issue":"6","key":"674_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/1060028014524174","volume":"48","author":"K Boyd","year":"2014","unstructured":"Boyd K, Hilas O. Alpha-adrenergic blockers for the treatment of lower-urinary-tract symptoms and dysfunction in women. Ann Pharmacother. 2014;48(6):711\u201322. \n                    https:\/\/doi.org\/10.1177\/1060028014524174\n                    \n                  .","journal-title":"Ann Pharmacother."},{"issue":"1","key":"674_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3346\/jkms.2010.25.1.117","volume":"25","author":"KS Lee","year":"2010","unstructured":"Lee KS, Han DH, Lee YS, Choo MS, Yoo TK, Park HJ, et al. Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: a 8-week prospective study. J Korean Med Sci. 2010;25(1):117\u201322. \n                    https:\/\/doi.org\/10.3346\/jkms.2010.25.1.117\n                    \n                  .","journal-title":"J Korean Med Sci."},{"issue":"6","key":"674_CR13","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s11255-012-0275-0","volume":"44","author":"LE Meyer","year":"2012","unstructured":"Meyer LE, Brown JN. Tamsulosin for voiding dysfunction in women. Int Urol Nephrol. 2012;44(6):1649\u201356. \n                    https:\/\/doi.org\/10.1007\/s11255-012-0275-0\n                    \n                  .","journal-title":"Int Urol Nephrol."},{"issue":"2","key":"674_CR14","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.juro.2014.01.091","volume":"192","author":"GE Tasian","year":"2014","unstructured":"Tasian GE, Cost NG, Granberg CF, Pulido JE, Rivera M, Schwen Z, et al. Tamsulosin and spontaneous passage of ureteral stones in children: a multi-institutional cohort study. J Urol. 2014;192(2):506\u201311. \n                    https:\/\/doi.org\/10.1016\/j.juro.2014.01.091\n                    \n                  .","journal-title":"J Urol."},{"issue":"5","key":"674_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336\u201341. \n                    https:\/\/doi.org\/10.1016\/j.ijsu.2010.02.007\n                    \n                  .","journal-title":"Int J Surg."},{"key":"674_CR16","unstructured":"OCEBM Levels of Evidence Working Group. \u201cThe Oxford 2011 Levels of Evidence\u201d. Oxford Centre for Evidence-Based Medicine. \n                    http:\/\/www.cebm.net\/index.aspx?o=5653\n                    \n                  . Accessed 10 Mar 2018."},{"key":"674_CR17","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 updated June 2010. \n                    https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\n                    \n                  . Accessed 21 June 2017."},{"key":"674_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/IJGM.S16063","volume":"4","author":"S Hajebrahimi","year":"2011","unstructured":"Hajebrahimi S, Asrbadr YA, Azaripour A, Sadeghi-Bazargani H. Effect of tamsulosin versus prazosin on clinical and urodynamic parameters in women with voiding difficulty: a randomized clinical trial. Int J Gen Med. 2011;4:35\u20139. \n                    https:\/\/doi.org\/10.2147\/IJGM.S16063\n                    \n                  .","journal-title":"Int J Gen Med."},{"issue":"10","key":"674_CR19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00192-011-1453-9","volume":"22","author":"SO Kim","year":"2011","unstructured":"Kim SO, Hwang EC, Oh KJ, Kwon D, Park K, Ryu SB. Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml\/s. Int Urogynecol J. 2011;22(10):1287\u201391. \n                    https:\/\/doi.org\/10.1007\/s00192-011-1453-9\n                    \n                  .","journal-title":"Int Urogynecol J."},{"issue":"2","key":"674_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S1015-9584(09)60146-9","volume":"30","author":"N Pummangura","year":"2007","unstructured":"Pummangura N, Kochakarn W. Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women. Asian J Surg. 2007;30(2):131\u20137.","journal-title":"Asian J Surg."},{"issue":"4","key":"674_CR21","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/j.1464-410X.2007.07162.x","volume":"100","author":"D Robinson","year":"2007","unstructured":"Robinson D, Cardozo L, Terpstra G, Bolodeoku J. Tamsulosin Study Group. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int. 2007;100(4):840\u20135.","journal-title":"BJU Int."},{"issue":"2","key":"674_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.aju.2015.02.007","volume":"13","author":"HA Aldaqadossi","year":"2015","unstructured":"Aldaqadossi HA, Shaker H, Saifelnasr M, Gaber M. Efficacy and safety of tamsulosin as a medical expulsive therapy for stones in children. Arab J Urol. 2015;13(2):107\u201311. \n                    https:\/\/doi.org\/10.1016\/j.aju.2015.02.007\n                    \n                  .","journal-title":"Arab J Urol."},{"issue":"5","key":"674_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jpurol.2011.09.008","volume":"8","author":"I Mokhless","year":"2012","unstructured":"Mokhless I, Zahran AR, Youssif M, Fahmy A. Tamsulosin for the management of distal ureteral stones in children: a prospective randomized study. J Pediatr Urol. 2012;8(5):544\u20138. \n                    https:\/\/doi.org\/10.1016\/j.jpurol.2011.09.008\n                    \n                  .","journal-title":"J Pediatr Urol."},{"issue":"5","key":"674_CR24","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.juro.2011.07.021","volume":"186","author":"Y Homsy","year":"2011","unstructured":"Homsy Y, Arnold P, Zhang W. Phase IIb\/III dose ranging study of tamsulosin as treatment for children with neuropathic bladder. J Urol. 2011;186(5):2033\u20139. \n                    https:\/\/doi.org\/10.1016\/j.juro.2011.07.021\n                    \n                  .","journal-title":"J Urol."},{"issue":"1","key":"674_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0022-5347(05)65407-9","volume":"167","author":"TJ Wilt","year":"2002","unstructured":"Wilt TJ, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J Urol. 2002;167(1):177\u201383.","journal-title":"J Urol."},{"issue":"10","key":"674_CR26","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/j.1742-1241.2008.01880.x","volume":"62","author":"JC Nickel","year":"2008","unstructured":"Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008;62(10):1547\u201359. \n                    https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01880.x\n                    \n                  .","journal-title":"Int J Clin Pract."},{"key":"674_CR27","unstructured":"Karesh K. Pediatric focused safety review: Flomax\u00ae (tamsulosin hydrochloride). U. S. Food and Drug Administration 2012. \n                    http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/PediatricAdvisoryCommittee\/UCM289947.pdf\n                    \n                  . Accessed 18 October 2016."},{"issue":"1","key":"674_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.juro.2015.06.097","volume":"195","author":"G Bailey","year":"2016","unstructured":"Bailey G, Vaughan L, Rose C, Krambeck A. Perinatal outcomes with tamsulosin therapy for symptomatic urolithiasis. J Urol. 2016;195(1):99\u2013103. \n                    https:\/\/doi.org\/10.1016\/j.juro.2015.06.097\n                    \n                  .","journal-title":"J Urol."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-018-0674-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0674-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0674-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T16:22:21Z","timestamp":1557418941000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-018-0674-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1007\/s40264-018-0674-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"8 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors. The authors received no direct compensation related to the development of the manuscript. Steven A. Kaplan and Bilal I. Chughtai have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was funded by Boehringer Ingelheim Pharmaceuticals, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}